The grades of five pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Auxilium Pharmaceuticals, Inc. (AUXL) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Auxilium Pharmaceuticals engages in developing and marketing pharmaceutical products primarily in the United States. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity, Cash Flow and Sales Growth, AUXL also gets A’s. The stock price has risen 20.8% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of AUXL stock.
This week, Forest Laboratories, Inc. (FRX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Forest Laboratories develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. At $67.49, the stock is above the 50-day moving average of $57.63. For more information, get Portfolio Grader’s complete analysis of FRX stock.
The rating of Watson Pharmaceuticals (WPI) moves up this week, rising from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Horizon Pharma, Inc. (HZNP) is seeing ratings go up from a B last week to an A this week. Horizon Pharma is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. With a price of $8.47, it is above the 50-day moving average of $7.02. For more information, get Portfolio Grader’s complete analysis of HZNP stock.
Cadence Pharmaceuticals, Inc. (CADX) improves from a C to a B rating this week. Cadence Pharmaceuticals focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada. The stock’s price of $11.60 is above the 50-day moving average of $9.12. For more information, get Portfolio Grader’s complete analysis of CADX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.